Rationale for treatment and study design of tailor: A randomized phase iii trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations

Clinical Lung Cancer

Volumn 12, Issue 2, 2011, Pages 138-141

  Farina, Gabriella ^a   Longo, Flavia ^b   Martelli, Olga ^c,q   Pavese, Ida ^d   Mancuso, Andrea ^e   Moscetti, Luca ^f   Labianca, Roberto ^g   Bertolini, Alessandro ^h   Cortesi, Enrico ^b   Farris, Antonio ⁱ   Fagnani, Daniele ^j   Cristina Locatelli, Maria ^k   Valmadre, Giuseppe ^l   Ardizzoia, Antonio ^m   Tomirotti, Maurizio ⁿ   Rulli, Eliana ^o   Chiara Garassino, Marina ^p   Scanni, Alberto ^p  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^d FATEBENEFRATELLI HOSPITAL   (Italy)

^e SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^f AUSL   (Italy)

^g OSPEDALI RIUNITI   (Italy)

^h Azienda Ospedaliera Della Valtellina e Valchiavenna   (Italy)

ⁱ UNIVERSITY OF SASSARI   (Italy)

^j AO Ospedale Civile Vimercate   (Italy)

^k SAN CARLO BORROMEO HOSPITAL   (Italy)

^l SOS DH Onco Ematologico Internistico SOC Medicina Ospedale EMorelli AOVV   (Italy)

^m A MANZONI HOSPITAL   (Italy)

ⁿ FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^o MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^p UNIVERSITY OF MILAN   (Italy)

^q Ospedale S Giovanni Addolorata   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; K RAS PROTEIN;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; LUNG NON SMALL CELL CANCER; MULTICENTER STUDY (TOPIC); OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; SMOKING; TREATMENT RESPONSE;

EID: 79959337566     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.03.008     Document Type: Article

References (16)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin Oncol 2001; 51:15-36.
2. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3543-51 Epub 2008 May 27.
3. Schiller JH, Harrington D, Belani CP. Comparison of four chemotherapy regimens for advanced NSCLC. N Engl J Med 2002; 346:92-8. (Pubitemid 34438899)
4. Shepherd F, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non small cell lung cancer previously treated with platinum based chemotherapy. J Clin Oncol 2000; 18:2095-103. (Pubitemid 30324363)
5. Hanna N, Shepherd F, Fossella F, et al. Randomized phase III trial of pemetrexed versus docetaxel in pts with non small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97. (Pubitemid 41079796)
6. Shepherd FA, Rodrigues Pereira J, et al. Erlotinib in previously treated non-smallcell lung cancer. N Engl J Med 2005; 353:123-32. (Pubitemid 41058344)
7. Gridelli C, Butts C, Ciardiello F, et al. An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial. Clin Lung Cancer 2008; 9:235-8.
8. Kim ES, Hirsch V, Mok T, et al. Gefitinib ersus Docetaxel in previously treated NSCLC (Interest): a randomized phase III trial. Lancet 2008; 372:1809-18.
9. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39. (Pubitemid 38637993)
10. Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004; 96:1133-41. (Pubitemid 39207049)
11. Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005; 11:5878-85. (Pubitemid 41170316)
12. Massutti B, Reguart N, López-Vivanco G, et al. First line erlotinib in stage IV NSCLC pts with mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). Ann Oncol 2006; 17:(abstract 720O, ix 216), ix 216.
13. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97:643-55. (Pubitemid 40812628)
14. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005; 23:8081-92. (Pubitemid 46657411)
15. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-37. (Pubitemid 41540110)
16. Hirsch FR, Varella-Garcia M, Bunn P, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer. J Clin Oncol 2006; 24:5034-42. (Pubitemid 46631407)